Semaglutide and pregnancy: what 'Ozempic babies' actually means

What did @injectorsnow actually say?

The creator made two distinct claims about so-called "Ozempic babies." First, that GLP-1 drugs like semaglutide and tirzepatide slow digestion enough to prevent oral contraceptives from being absorbed properly, reducing their effectiveness. Second, that weight loss from these medications improves fertility, making pregnancy more likely once people stop taking them. The video ends with a pitch for compounded semaglutide and tirzepatide through their clinics, which they describe as "the generic version" of Ozempic and Mounjaro. That framing is a problem, and we'll get to it.

To the creator's credit, this is a real phenomenon people are genuinely experiencing and asking about. The underlying question deserves a straight answer. Unfortunately, the explanation they gave was partly wrong and partly oversimplified.

Does the science back this up?

The oral contraceptive absorption claim has some plausibility but the evidence is thin and the mechanism is overstated. The fertility-through-weight-loss claim is better supported.

GLP-1 receptor agonists do slow gastric emptying, a well-documented effect studied by Nauck et al. (2021, Diabetes Care). The concern that this delays oral contraceptive absorption has been raised in pharmacokinetic literature. Novo Nordisk's own prescribing information for semaglutide notes that it may affect absorption of co-administered oral medications. However, a specific study by Marbury et al. (2011, Clinical Pharmacokinetics) on liraglutide found that while it delayed the time to peak concentration of oral contraceptives, it did not meaningfully reduce overall bioavailability. The clinical significance of this for semaglutide specifically is not yet well-established in head-to-head data.

On fertility, the connection between weight loss and improved reproductive outcomes is better documented. Research by Legro et al. (2015, New England Journal of Medicine) showed that weight loss in women with PCOS, one of the most common causes of anovulatory infertility, significantly improved ovulation rates. Obesity is associated with elevated estrogen from adipose tissue, which can suppress ovulation. Losing weight can restore normal hormonal cycling.

What did they get wrong (or right)?

The fertility-through-weight-loss point is largely accurate, and credit is due for raising it. It is a real mechanism backed by real research, particularly for women with PCOS or obesity-related hormonal disruption.

The oral contraceptive claim is where things go sideways. Saying the body "won't be able to utilize the hormone the way that it normally would" overstates what the current evidence actually shows. Delayed absorption is not the same as failed absorption. No large clinical trial has confirmed that GLP-1 drugs cause contraceptive failure at a population level. The creator presents a plausible hypothesis as an established fact, which it is not.

The bigger problem is the language around compounded drugs. Calling compounded semaglutide "the generic version of Ozempic" is inaccurate and potentially misleading. Compounded semaglutide is not FDA-approved, has not gone through the same bioequivalence testing as a generic drug would, and cannot be legally marketed as equivalent to Ozempic. The FDA has specifically flagged this distinction. This claim should not go unchallenged.

What should you actually know?

If you are on GLP-1 therapy and using oral contraceptives, talk to your prescriber. The concern about absorption is real enough that some guidance recommends using a backup contraceptive method, particularly during the dose escalation phase when gastric emptying effects are strongest. This is a reasonable precaution even without definitive trial data.

If you have experienced infertility linked to obesity or PCOS, weight loss, whether through GLP-1 medications or other means, may genuinely improve your reproductive outcomes. That is worth discussing with a reproductive endocrinologist, not a TikTok comments section.

On the compounding question: the FDA placed semaglutide on its shortage list for a period, which allowed compounding pharmacies to legally produce versions of it. As of 2025, the FDA has stated that shortage conditions have resolved for some formulations, which has significant regulatory implications for compounded products. Compounded semaglutide and tirzepatide are not generics. They have not been tested for bioequivalence. Anyone considering them should ask their provider pointed questions about sourcing, testing, and regulatory status.